View in EDS HTML Full Text PDF Full Text

Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab.

Saved in:
Bibliographic Details
Title: Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab.
Authors: Gebrael G; Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Jo Y; Cancer Biostatistics, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Ozay ZI; Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Nandakumar V; Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Cigliola A; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy., Tateo V; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy., Lin E; Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Ostrowski M; Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Sayegh N; Division of Hematology and Oncology, Department of Internal Medicine, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA., Murdock E; Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Mathew Thomas V; Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Gupta S; Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Agarwal N; Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Swami U; Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Source: Bladder cancer (Amsterdam, Netherlands) [Bladder Cancer] 2026 Mar 29; Vol. 12 (1), pp. 23523735261437911. Date of Electronic Publication: 2026 Mar 29 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Sage Publications Country of Publication: United States NLM ID: 101668567 Publication Model: eCollection Cited Medium: Internet ISSN: 2352-3735 (Electronic) Linking ISSN: 23523727 NLM ISO Abbreviation: Bladder Cancer Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41918797
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Gebrael+G%22">Gebrael G</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.<br /><searchLink fieldCode="AU" term="%22Jo+Y%22">Jo Y</searchLink>; Cancer Biostatistics, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.<br /><searchLink fieldCode="AU" term="%22Ozay+ZI%22">Ozay ZI</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.<br /><searchLink fieldCode="AU" term="%22Nandakumar+V%22">Nandakumar V</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.<br /><searchLink fieldCode="AU" term="%22Cigliola+A%22">Cigliola A</searchLink>; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Tateo+V%22">Tateo V</searchLink>; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Lin+E%22">Lin E</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.<br /><searchLink fieldCode="AU" term="%22Ostrowski+M%22">Ostrowski M</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.<br /><searchLink fieldCode="AU" term="%22Sayegh+N%22">Sayegh N</searchLink>; Division of Hematology and Oncology, Department of Internal Medicine, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.<br /><searchLink fieldCode="AU" term="%22Murdock+E%22">Murdock E</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.<br /><searchLink fieldCode="AU" term="%22Mathew+Thomas+V%22">Mathew Thomas V</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.<br /><searchLink fieldCode="AU" term="%22Gupta+S%22">Gupta S</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.<br /><searchLink fieldCode="AU" term="%22Agarwal+N%22">Agarwal N</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.<br /><searchLink fieldCode="AU" term="%22Swami+U%22">Swami U</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101668567%22">Bladder cancer (Amsterdam, Netherlands)</searchLink> [Bladder Cancer] 2026 Mar 29; Vol. 12 (1), pp. 23523735261437911. <i>Date of Electronic Publication: </i>2026 Mar 29 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Sage+Publications%22">Sage Publications </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101668567 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2352-3735 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223523727%22">23523727 </searchLink><i>NLM ISO Abbreviation: </i>Bladder Cancer <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41918797
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1177/23523735261437911
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 23523735261437911
    Titles:
      – TitleFull: Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gebrael G
      – PersonEntity:
          Name:
            NameFull: Jo Y
      – PersonEntity:
          Name:
            NameFull: Ozay ZI
      – PersonEntity:
          Name:
            NameFull: Nandakumar V
      – PersonEntity:
          Name:
            NameFull: Cigliola A
      – PersonEntity:
          Name:
            NameFull: Tateo V
      – PersonEntity:
          Name:
            NameFull: Lin E
      – PersonEntity:
          Name:
            NameFull: Ostrowski M
      – PersonEntity:
          Name:
            NameFull: Sayegh N
      – PersonEntity:
          Name:
            NameFull: Murdock E
      – PersonEntity:
          Name:
            NameFull: Mathew Thomas V
      – PersonEntity:
          Name:
            NameFull: Gupta S
      – PersonEntity:
          Name:
            NameFull: Agarwal N
      – PersonEntity:
          Name:
            NameFull: Swami U
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 29
              M: 03
              Text: 2026 Mar 29
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2352-3735
          Numbering:
            – Type: volume
              Value: 12
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Bladder cancer (Amsterdam, Netherlands)
              Type: main
ResultId 1